Abstract
Occult papillary thyroid carcinoma (OPTC) has been defined as a PTC with a maximal tumor dimension of 1.5 cm or less with or without neck nodal metastases (NNM). It is increasingly prevalent, now accounting for the majority of PTCs diagnosed in the twenty-first century. About one in four is multicentric and one in three node-positive at presentation. Ninety-six percent are noninvasive and 99.5 % are localized to the neck. The majority are treated initially with near-total or total thyroidectomy, a minority by unilateral lobectomy. Therapeutic nodal dissection is performed for N1b disease. Controversy surrounds the role of prophylactic central compartment dissection with removal of subclinical level VI nodal metastases. Also, there is ongoing controversy regarding the acceptability of unilateral lobectomy as a definitive primary surgical procedure for OPTC. Radioiodine remnant ablation was performed in the 1980s in almost 50 % of OPTC patients, but currently, most (>80 %) do not receive ablative therapy, since it does not reduce recurrence rates at any site. Patients treated conventionally for OPTC can be reassured that they will enjoy a normal life expectancy and 90 % will never see a neck nodal recurrence during 40 years after initial surgery. It is probable that the observed excellent outcomes relate more to the indolent biologic nature of OPTC, rather than the efficacy of the variable initial management policies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- TSH:
-
Thyroid stimulating hormone thyrotropin
- US:
-
Ultrasound
- PTC:
-
Papillary thyroid carcinoma
- cTNM:
-
Clinical tumor node metastasis
- pTNM:
-
Postoperative tumor node metastasis
- AJCC:
-
American Joint Committee on Cancer
- UICC:
-
International Union Against Cancer
- CSM:
-
Cause-specific mortality
- AGES:
-
Age grade extent size
- MACIS:
-
Metastases age completeness invasion size
- AMES:
-
Age metastases extrathyroid size
- NNM:
-
Neck nodal metastases
- TST:
-
Thyroxine-suppressive therapy
- Tg:
-
Thyroglobulin
- RAI:
-
Radioactive iodine
- RRA:
-
Radioiodine remnant ablation
- WBS:
-
Whole body scan
- CT:
-
Computerized tomographic
- OPTC:
-
Occult papillary thyroid carcinoma
- DM:
-
Distant metastases
- BLR:
-
Bilateral lobar resection
- RNR:
-
Regional neck recurrence
- ATA:
-
American Thyroid Association
- ETA:
-
European Thyroid Association
- FDA:
-
Food and Drug Administration
- BST:
-
Bilateral subtotal thyroidectomy
- UL:
-
Unilateral lobectomy
- NTT:
-
Near-total thyroidectomy
- TT:
-
Total thyroidectomy
- LRR:
-
Locoregional recurrence rate
- R:
-
Recommendation
- MSKCC:
-
Memorial Sloan Kettering Cancer Center
- NCDB:
-
National cancer data base
- SEER:
-
Surveillance epidemiology, and end results
References
Woolner LB, Lemmon ML, Beahrs OH, Black BM, Keating Jr FR. Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. J Clin Endocrinol. 1960;20:89–105.
Hubert Jr JP, Kiernan PD, Beahrs OH, McConahey WM, Woolner LB. Occult papillary carcinoma of the thyroid. Arch Surg. 1980;115:394–8.
Thompson NW, Nishiyama RH, Harness JK. Thyroid carcinoma: current controversies. Curr Probl Surg. 1978;15:1–67.
Grant CS, Stulak J, Thompson GB, Richards ML, Reading CC, Hay ID. Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999–2006. World J Surg. 2010;34:1239–46.
Hay ID. Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best? World J Surg. 2010;34:1291–3.
Grant CS. Papillary thyroid cancer: strategies for optimal individualized surgical management. Clin Ther. 2014;36:1117–26.
Nixon IJ, Shaha AR. Management of regional nodes in thyroid cancer. Oral Oncol. 2013;49:671–5.
Giordano D, Valcavi R, Thompson GB, Pedroni C, Renna L, Gradoni P, Brabieri V. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid. 2012;22:911–7.
Paphasavit A, Thompson GB, Hay ID, Grant CS, van Heereden JA, Ilstrup DM, Schleck C, Goellner JR. Follicular and Hurthle cell thyroid neoplasms: is frozen-section evaluation worthwhile? Arch Surg. 1997;132:674–9.
McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61:978–96.
Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma; a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–95.
Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990;19:545–76.
Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, Fagin J, Ghossein R. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid. 2010;20:1085–93.
Ito Y, Miyauchi A, Kihara M, Kobayashi K, Miya A. Prognostic values of clinical lymph node metastases and macroscopic extension in papillary thyroid carcinoma. Endocrinol J. 2014;61:745–60.
Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg. 2006;30:780–6.
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1987;114:1050–8.
Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.
Hay ID. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Assoc. 2002;113:241–60.
Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692–700.
Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract. 2007;13:521–33.
Randolph GW, Thompson GB, Branovan DI, Tuttle RM. Treatment of thyroid cancer 2007 – a basic review. Int J Radiat Oncol Biol Phys. 2007;69 Suppl 2:892–7.
Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 2002;178:699–704.
Heilo A, Sigstad E, Fagerlid KH, Haskjold OI, Groholt KK, Berner A, Bjoro T, Jorgensen LH. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96:2750–5.
Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery. 2013;154:1448–55.
Hay ID, Mullan BP, McIver B, Maurer M, Powell CC, Oberg AL, Wiseman GA, Goellner JR, Gorman CA. Radioiodine remnant ablation does not decrease recurrence rates in patients with small papillary thyroid carcinomas. J Nucl Med. 2002;43 Suppl 5:12P.
Cappelli C, Castellano M, Braga M, Gandossi E, Pirola I, De Martino E. Aggressiveness and outcome of papillary thyroid carcinoma versus microcarcinoma: a mono-institutional experience. J Surg Oncol. 2007;95:555–60.
Hay ID, Hutchinson ME, Reinalda MS, Grant CS, McIver B, Thompson GB. Woolner’s “occult” papillary thyroid cancer revisited: 1421 cases treated at one institution during a 60-year period. Proceedings 90th Annual Meeting, Endocrine Society, San Francisco, CA; June 2008.
Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Shah JP. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–9.
Nixon IJ, Ganly I, Patel SG, Morris LG, Palmer FL, Thomas D, Tuttle RM, Shah JP, Shaha AR. Observation of clinically negative central compartment lymph nodes in papillary thyroid carcinoma. Surgery. 2013;154:1166–73.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Sherman SI, Tuttle RM, The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SL, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;11:1–48.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff K, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 (in press).
Hay ID, McDougall IR, Sisson JC. Perspective: the case against radioiodine remnant ablation in patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1395–7.
Mazzaferri EL. A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental dissections and selective use of radioiodine. J Clin Endocrinol Metab. 2009;94:1086–8.
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–7.
Abdelgadir AM, Pura J, Goffredo P, Dinan M, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab. 2015;100:115–21.
Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 2015;4:52–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hay, I.D. (2016). A Case of a Papillary Thyroid Cancer with Lymph Node Metastases Found on Prophylactic Central Neck Dissection (Subclinical Disease, Micrometastases). In: Cooper, D., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22401-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-22401-5_8
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22400-8
Online ISBN: 978-3-319-22401-5
eBook Packages: MedicineMedicine (R0)